<DOC>
	<DOCNO>NCT02862483</DOCNO>
	<brief_summary>The efficacy safety combination tamsulosin tadalafil men low urinary tract symptom due benign prostatic hyperplasia Erectile Dysfunction : randomize , double blind , parallel design , active control , multi-center , phase 3 clinical trial</brief_summary>
	<brief_title>The Efficacy Safety Combination Tamsulosin Tadalafil Men With Lower Urinary Tract Symptoms Due Benign Prostatic Hyperplasia Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Visit1 Male age 45 year old old Subjects PSA ≤ 4.0 ng/mL Visit2 Subjects Total IPSS score ≥ 13 Subjects IIEFEF domain ≤ 24 point 3 question 3 4 Subjects hypersensitivity investigational product sulfa medication</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>